The proposed career development training plan will provide the candidate, Dr. Amod Sarnaik, with a pathway to independence as a researcher. Dr. Sarnaik's long term career goal is to become an established translational scientist with expertise in surgically-oriented immune-based early phase clinical trials. Dr. Sarnaik's immediate goal is to acquire specific skills in clinical and translational laboratory research, biostatistics, and grnt writing. The training plan includes didactic and practical experiences in each of these elements and is designed to capitalize on existing resources at Moffitt Cancer Center as well as the specific expertise of the mentors included in the training plan. The proposed research plan is a logical extension of Dr. Sarnaik's preliminary data. This includes implementation of a phase I clinical trial that combines co- stimulatory antibodies and adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) for patients with stage IV melanoma that are unresectable for curative intent. Adoptive cell therapy is a recent innovation in immunotherapy for metastatic melanoma, and combination with co-stimulatory antibodies has the potential to improve patient outcomes. This trial will determine the safety and feasibility of this combination treatment. Additionally, the mechanisms by which co-stimulation enhances outcomes will be determined by investigating known factors important for T cell-mediated anti-tumor responses. Results will directly lead to the development of a phase II trial. The career development training plan will involve close mentoring by Dr. Jeffrey Weber, as well as oversight by an advisory committee. The co-mentors of the grant will provide additional training in phase I clinical trial design and analysis, translational laboratory research, clinical trial development, and biostatistics. Key elements of the career development plan include: weekly interactions with Dr. Weber, rotations in Clinical Pharmacology, the Clinical Research Unit (Phase I/II trial monitoring and care), and the laboratory of Dr. James Mul?. In addition, training in biostatistics by Dr. Ji-Hyun Lee and training in grant writing will be obtained. It is anticipated that these experiences will lead to a R01 submission by the end of the term of the grant. Moffitt Cancer Center provides an ideal and unique training environment for this opportunity. The training proposed in this K23 training grant will allow Dr. Sarnaik to transition to an independent translational and clinical trial researcher.

Public Health Relevance

For the research plan of this K23 proposal, I propose a phase I clinical trial combining co-stimulatory antibodies and adoptive cell therapy with tumor-infiltratin lymphocytes (TIL) for patients with stage IV melanoma that are unresectable for cure. Patient- derived specimens from this trial will be used to determine the mechanisms by which the co-stimulatory antibodies enhance adoptive cell therapy. The long term goal of this project is to apply our expanding knowledge of T cell biology to improve the promising, emerging treatment of adoptive cell therapy for metastatic melanoma.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lim, Susan E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
H. Lee Moffitt Cancer Center & Research Institute
United States
Zip Code
Poch, Michael; Hall, MacLean; Joerger, Autumn et al. (2018) Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer. Oncoimmunology 7:e1476816
Liu, Hao; Weber, Amy; Morse, Jennifer et al. (2018) T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model. PLoS One 13:e0196033
Mullinax, John E; Hall, MacLean; Prabhakaran, Sangeetha et al. (2018) Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Front Oncol 8:44
Oliver, Daniel E; Sondak, Vernon K; Strom, Tobin et al. (2018) Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience. Melanoma Manag 5:MMT02
Mahajan, Nupam P; Malla, Pavani; Bhagwat, Shambhavi et al. (2017) WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of IDH2 gene expression. Oncotarget 8:106352-106368
Dossett, Lesly A; Castner, Nicholas B; Pow-Sang, Julio M et al. (2016) Robotic-Assisted Transperitoneal Pelvic Lymphadenectomy for Metastatic Melanoma: Early Outcomes Compared with Open Pelvic Lymphadenectomy. J Am Coll Surg 222:702-9
Doepker, Matthew P; Thompson, Zachary J; Harb, Jennifer N et al. (2016) Dermal melanoma: A report on prognosis, outcomes, and the utility of sentinel lymph node biopsy. J Surg Oncol 113:98-102
Sung, Hyeran; Kanchi, Krishna L; Wang, Xue et al. (2016) Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation. Oncotarget 7:23885-96
Liu, Hao; Innamarato, Pasquale Patrick; Kodumudi, Krithika et al. (2016) Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1. Oncotarget 7:37893-37905
Hall, MacLean; Liu, Hao; Malafa, Mokenge et al. (2016) Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors. J Immunother Cancer 4:61

Showing the most recent 10 out of 23 publications